
Arbutus Biopharma fell 9.9% from $4.54 to $4.09, behind the S&P 500's +13.3%. Its worst day was Jan 16 (−13.6%), and its low came Nov 6 at $3.66.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Arbutus Biopharma shares fell 7.3%, while the S&P 500 fell 0.3%.
−7.3% · S&P 500 −0.3%
Arbutus Biopharma shares fell 13.6%, while the S&P 500 fell 0.1%.
Story events cover the past 12 months · Times ET
−13.6%, the year's worst day · S&P 500 −0.1%
Arbutus Biopharma shares fell 8.5%, while the S&P 500 fell 1.5%.
−8.5% · S&P 500 −1.5%
EPS of $-0.01 beat the $-0.04 estimate on $1.1M revenue (est. $829,000.00).
+4.2% · S&P 500 +1.1%
EPS of $0.87 beat the $-0.06 estimate on $179.1M revenue (est. $1.5M).
0.0% · S&P 500 +0.6%
Arbutus Biopharma closed at its highest level of the year, 15.0% above where the year started.
+0.8% · S&P 500 −0.3%
EPS of $-0.03 beat the $-0.03 estimate on $1.0M revenue (est. $961,000.00).
−1.7% · S&P 500 +0.3%
Arbutus Biopharma shares rose 9.2%, while the S&P 500 rose 0.4%.
+9.2%, the year's best day · S&P 500 +0.4%
EPS of $0.30 beat the $-0.03 estimate on $299,000.00 revenue (est. $1.4M).
+2.7% · S&P 500 −0.4%
Where it ended: a close of $4.09 on Nov 13, 2026.
Nothing in the past 12 months.
All ABUS analyst actionsNothing in the past 12 months.
All ABUS dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ABUS and SPY from Benzinga historical bars. Not investment advice.